X-Chromosome Reactivation Silences the NLRP3 Inflammasome via Dosage-Dependent Deubiquitinating Enzymes

Lena V.· Mar 21, 2026

Mechanism: X-chromosome reactivation in XX cells increases deubiquitinase enzymes (OTUD5/USP9X), which remove activating K63-ubiquitin chains from the NLRP3 inflammasome, dampening its activity. Readout: Readout: This leads to reduced IL-1β/IL-18 release and a significant decrease in overall inflammation, contributing to a longevity advantage.

Hypothesis

Aging triggers widespread escape from X-chromosome inactivation (XCI) in XX cells, leading to increased expression of X-linked deubiquitinating enzymes such as OTUD5 and USP9X. These enzymes preferentially remove K63-linked ubiquitin chains from the NLRP3 inflammasome complex, dampening its activation and reducing inflammasome-driven inflammation. It's a direct link between X‑chromosome dosage and the lower inflammaging observed in females, offering a testable explanation for the longevity advantage of XX genotypes.

Mechanistic Basis

The inactive X chromosome (Xi) harbors a high density of immune‑regulatory genes, including the deubiquitinases OTUD5 (encoded by OTUD5) and USP9X (encoded by USP9X), both of which have been shown to escape XCI in aged mouse brain [1].
OTUD5 already appears in the list of Xi‑escaped genes that upregulate ubiquitin‑mediated protein degradation, suggesting a role in editing ubiquitin chains on signaling platforms [2].
USP9X is known to stabilize proteins by removing degradative ubiquitin modifications and has been implicated in NLRP3 regulation in macrophages [3].
K63‑linked ubiquitination is a critical activating signal for NLRP3; removal of these chains by OTUD5/USP9X converts the inflammasome to an inactive state, curbing IL‑1β and IL‑18 release.
In XY cells, the single X chromosome provides only one allele of each deubiquitinase, limiting the capacity to counteract NLRP3 activation when stress or damage accumulates with age.

Testable Predictions

Cell‑type specificity – Microglia and astrocytes from aged XX mice will show higher OTUD5/USP9X protein levels and lower NLRP3 K63‑ubiquitination than XY counterparts; this difference will disappear when XCI escape is genetically blocked (e.g., by deleting Xist only on the inactive X).
Pharmacological mimic – Treating XY microglia with a small‑molecule activator of OTUD5/USP9X activity should reduce NLRP3 inflammasome activation to levels seen in XX cells, as measured by ASC speck formation and caspase‑1 cleavage.
In vivo longevity – XX mice with a microglia‑specific knockout of both Otud5 and Usp9x will lose their survival advantage over XY littermates, despite having two X chromosomes, confirming that the deubiquitinases mediate the protective effect.
Human correlative – In centenarian women, peripheral blood mononuclear cells will exhibit elevated OTUD5/USP9X expression and reduced NLRP3 activity compared with age‑matched men; loss of Y chromosome (LOY) in men will correlate with lower deubiquitinase expression and higher inflammasome markers.

Potential Implications

If validated, this hypothesis reframes the X chromosome not merely as a backup copy but as a dynamic regulator of innate immunity through dosage‑sensitive deubiquitination. It suggests that boosting OTUD5/USP9X activity could be a sex‑neutral strategy to mitigate inflammaging, while also highlighting why therapies targeting the NLRP3 inflammasome may show divergent efficacy between sexes. Finally, it offers a mechanistic explanation for the observation that skewed XCI—which limits escape—associates with higher cardiovascular disease and cancer risk in women, as reduced deubiquitinase activity would permit unchecked inflammasome signaling.

[1] https://www.science.org/doi/10.1126/sciadv.ads8169 [2] https://www.science.org/doi/10.1126/sciadv.ads8169 [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC6050741/ [4] https://doi.org/10.1101/2025.06.01.25328624 [5] https://elifesciences.org/articles/78263

Hypothesis

Mechanistic Basis

The inactive X chromosome (Xi) harbors a high density of immune‑regulatory genes, including the deubiquitinases OTUD5 (encoded by OTUD5) and USP9X (encoded by USP9X), both of which have been shown to escape XCI in aged mouse brain [1].

OTUD5 already appears in the list of Xi‑escaped genes that upregulate ubiquitin‑mediated protein degradation, suggesting a role in editing ubiquitin chains on signaling platforms [2].

USP9X is known to stabilize proteins by removing degradative ubiquitin modifications and has been implicated in NLRP3 regulation in macrophages [3].

K63‑linked ubiquitination is a critical activating signal for NLRP3; removal of these chains by OTUD5/USP9X converts the inflammasome to an inactive state, curbing IL‑1β and IL‑18 release.

In XY cells, the single X chromosome provides only one allele of each deubiquitinase, limiting the capacity to counteract NLRP3 activation when stress or damage accumulates with age.

Testable Predictions

Cell‑type specificity – Microglia and astrocytes from aged XX mice will show higher OTUD5/USP9X protein levels and lower NLRP3 K63‑ubiquitination than XY counterparts; this difference will disappear when XCI escape is genetically blocked (e.g., by deleting Xist only on the inactive X).

Pharmacological mimic – Treating XY microglia with a small‑molecule activator of OTUD5/USP9X activity should reduce NLRP3 inflammasome activation to levels seen in XX cells, as measured by ASC speck formation and caspase‑1 cleavage.

In vivo longevity – XX mice with a microglia‑specific knockout of both Otud5 and Usp9x will lose their survival advantage over XY littermates, despite having two X chromosomes, confirming that the deubiquitinases mediate the protective effect.

Human correlative – In centenarian women, peripheral blood mononuclear cells will exhibit elevated OTUD5/USP9X expression and reduced NLRP3 activity compared with age‑matched men; loss of Y chromosome (LOY) in men will correlate with lower deubiquitinase expression and higher inflammasome markers.

Potential Implications